NYGGF4, an obesity-related gene, is proposed to be involved in the development of insulin resistance; however, the underlying molecular mechanisms remain unclear. In the present analysis, NimbleGen tiling arrays were used to determine the patterns of genomic DNA methylation at CpG islands and promoters in NYGGF4-overexpression adipocytes. A total of 2352 CpG dinucleotides in 2018 genes and 3490 CpG dinucleotides in 3064 genes were found to be hypermethylated or hypomethylated, respectively, in NYGGF4-overexpression adipocytes. Furthermore, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway analysis revealed enrichment of biological processes associated with energy metabolism and signal transduction events, including the peroxisome proliferator-activated receptor gamma (PPARγ) signaling pathway, and mitogen-activated protein kinases(MAPK) and Ras homolog gene family, member A (RhoA) signaling. These data demonstrate that differentially methylated genes are significantly overrepresented in NYGGF4-overexpression adipocytes, providing valuable clues for further exploration of the role of NYGGF4 in insulin sensitivity regulation.
References
[1]
Campion, J.; Milagro, F.I.; Martinez, J.A. Individuality and epigenetics in obesity. Obes. Rev 2009, 10, 383–392.
[2]
Bird, A. Perceptions of epigenetics. Nature 2007, 2447, 396–398.
[3]
Dolinoy, D.C.; Jirtle, R.L. Environmental epigenomics in human health and disease. Environ. Mol. Mutagen. 2008, 49, 4–8.
[4]
Yokomori, N.; Tawata, M.; Onaya, T. DNA demethylation during the differentiation of 3T3-L1 cells affects the expression of the mouse GLUT4 gene. Diabetes 1999, 48, 685–690.
[5]
Melzner, I.; Scott, V.; Dorsch, K.; Fischer, P.; Wabitsch, M.; Brüderlein, S.; Hasel, C.; M？ller, P.; Stoger, R. In vivo methylation patterns of the leptin promoter in human and mouse. Epigenetics 2006, 1, 155–162.
[6]
Noer, A.; S？rensen, A.L.; Boquest, A.C.; Collas, P. Stable CpG hypomethylation of adipogenic promoters in freshly isolated, cultured, and differentiated mesenchymal stem cells from adipose tissue. Mol. Biol. Cell 2006, 17, 3543–3556.
[7]
Campión, J.; Milagro, F.I.; Goyenechea, E.; Martínez, J.A. TNF-alpha promoter methylation as a predictive biomarker for weight-loss response. Obesity (Silver Spring) 2009, 17, 1293–1297.
[8]
Cordero, P.; Campion, J.; Milagro, F.I.; Goyenechea, E.; Steemburgo, T.; Javierre, B.M.; Martinez, J.A. Leptin and TNF-alpha promoter methylation levels measured by MSP could predict the response to a low-calorie diet. J. Physiol. Biochem 2011, 67, 463–470.
[9]
Junien, C.; Nathanielsz, P. Report on the IASO Stock Conference 2006: Early and lifelong environmental epigenomic programming of metabolic syndrome, obesity and type II diabetes. Obes. Rev 2007, 8, 487–502.
[10]
Rüegg, J.; Cai, W.; Karimi, M.; Kiss, N.B.; Swedenborg, E.; Larsson, C.; Ekstr？m, T.J.; Pongratz, I. Epigenetic regulation of glucose transporter 4 by estrogen receptor β. Mol. Endocrinol 2011, 25, 2017–2028.
[11]
Zhang, C.M.; Chen, X.H.; Wang, B.; Liu, F.; Chi, X.; Tong, M.L.; Ni, Y.H.; Chen, R.H.; Guo, X.R. Over-expression of NYGGF4 inhibits glucose transport in 3T3-L1 adipocytes via attenuated phosphorylation of IRS-1 and Akt. Acta Pharmacol. Sin 2009, 30, 120–124.
[12]
Wu, W.L.; Gan, W.H.; Tong, M.L.; Li, X.L.; Dai, J.Z.; Zhang, C.M.; Guo, X.R. Over-expression of NYGGF4 (PID1) inhibits glucose transport in skeletal myotubes by blocking the IRS1/PI3K/AKT insulin pathway. Mol. Genet. Metab 2001, 102, 374–377.
[13]
Rauch, T.A.; Pfeifer, G.P. The MIRA method for DNA methylation analysis. Methods Mol. Biol 2009, 507, 65–75.
[14]
Lowe, X.R.; Lu, X.; Marchetti, F.; Wyrobek, A.J. The expression of Troponin T1 gene is induced by ketamine in adult mouse brain. Brain Res 2007, 1174, 7–17.
[15]
Kobayashi, T.; Patrick, S.E.; Kobayashi, M. Ala scanning of the inhibitory region of cardiac troponin I. J. Biol. Chem 2009, 284, 20052–20060.
[16]
Choi, H.; Kim, S.J.; Park, S.S.; Chang, C.; Kim, E. TR4 activates FATP1 gene expression to promote lipid accumulation in 3T3-L1 adipocytes. FEBS Lett 2011, 585, 2763–2767.
[17]
Bogan, J.S.; Hendon, N.; McKee, A.E.; Tsao, T.S.; Lodish, H.F. Functional cloning of TUG as a regulator of GLUT4 glucose transporter trafficking. Nature 2003, 425, 727–733.
[18]
Van Berkel, T.J.; Van Eck, M.; Herijgers, N.; Fluiter, K.; Nion, S. Scavenger receptor classes A and B. Their roles in atherogenesis and the metabolism of modified LDL and HDL. Ann. NY Acad. Sci. 2000, 902, 113–26. discussion 126–127.
[19]
Dreyer, C.; Krey, G.; Keller, H.; Givel, F.; Helftenbein, G.; Wahli, W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992, 68, 879–887.
[20]
Bugge, A.; Mandrup, S. Molecular mechanisms and genome-wide aspects of PPAR subtype specific transactivation. PPAR Res. 2010, doi:10.1155/2010/169506.
[21]
Shearer, B.G.; Billin, A.N. The next generation of PPAR drugs: Do we have the tools to find them? Biochim. Biophys. Acta 2007, 1771, 1082–1093.
[22]
Ferré, P. The biology of peroxisome proliferator-activated receptors: Relationship with lipid metabolism and insulin sensitivity. Diabetes 2004, 53 Suppl 1, S43–50.
Manna, P.R.; Stocco, D.M. The role of specific mitogen-activated protein kinase signaling cascades in the regulation of steroidogenesis. J. Signal Transduct. 2011, doi:10.1155/2011/821615.
[25]
Sale, E.M.; Atkinson, P.G.; Sale, G.J. Requirement of MAP kinase for differentiation of fibroblasts to adipocytes, for insulin activation of p90 S6 kinase and for insulin or serum stimulation of DNA synthesis. EMBO J 1995, 14, 674–684.
[26]
Bost, F.; Aouadi, M.; Caron, L.; Even, P.; Belmonte, N.; Prot, M.; Dani, C.; Hofman, P.; Pagès, G.; Pouysségur, J.; et al. The extracellular signal-regulated kinase isoform ERK1 is specifically required for in vitro and in vivo adipogenesis. Diabetes 2005, 54, 402–411.
[27]
Gehart, H.; Kumpf, S.; Ittner, A.; Ricci, R. MAPK signalling in cellular metabolism: Stress or wellness? EMBO Rep 2010, 11, 834–840.
[28]
Fujishiro, M.; Gotoh, Y.; Katagiri, H.; Sakoda, H.; Ogihara, T.; Anai, M.; Onishi, Y.; Ono, H.; Abe, M.; Shojima, N.; et al. Three mitogen-activated protein kinases inhibit insulin signaling by different mechanisms in 3T3-L1 adipocytes. Mol. Endocrinol 2003, 17, 487–497.
[29]
Walsh, C.T.; Stupack, D.; Brown, J.H. G protein-coupled receptors go extracellular: RhoA integrates the integrins. Mol. Interv 2008, 8, 165–173.
[30]
Standaert, M.; Bandyopadhyay, G.; Galloway, L.; Ono, Y.; Mukai, H.; Farese, R. Comparative effects of GTPgammaS and insulin on the activation of Rho, relationship to glucose transport. J. Biol. Chem 1998, 273, 7470–7477.
[31]
Takaguri, A.; Satoh, K.; Itagaki, M.; Tokumitsu, Y.; Ichihara, K. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. J. Pharmacol. Sci 2008, 107, 80–89.
[32]
Herz, J.; Strickland, D.K. LRP: A multifunctional scavenger and signaling receptor. J. Clin. Invest 2001, 108, 779–784.
[33]
Ma, Z.H.; Yang, Y.; Zou, L.; Luo, K.Y. 125I seed irradiation induces up-regulation of the genes associated with apoptosis and cell cycle arrest and inhibits growth of gastric cancer xenografts. J. Exp. Clin. Cancer Res. 2012, 31, 61.
[34]
Ashburner, M.; Ball, C.A.; Blake, J.A.; Botstein, D.; Butler, H.; Cherry, J.M.; Davis, A.P.; Dolinski, K.; Dwight, S.S.; Eppig, J.T.; et al. Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet 2002, 25, 25–29.
[35]
Dupuy, D.; Bertin, N.; Hidalgo, C.A.; Venkatesan, K.; Tu, D.; Lee, D.; Rosenberg, J.; Svrzikapa, N.; Blanc, A.; Carnec, A.; et al. Genome-scale analysis of in vivo spatiotemporal promoter activity in Caenorhabditis elegans. Nat. Biotechnol 2007, 25, 663–668.
[36]
Schlitt, T.; Palin, K.; Rung, J.; Dietmann, S.; Lappe, M.; Ukkonen, E.; Brazma, A. Fromgene networks to gene function. Genome Res 2003, 13, 2568–2576.
[37]
Yi, M.; Horton, J.D.; Cohen, J.C.; Hobbs, H.H.; Stephens, R.M. WholePathwayScope: A comprehensive pathway-based analysis tool for high-throughput data. BMC Bioinformatics 2006, 7, 30.
